Data available at <https://doi.org/10.5061/dryad.n14p52b>

Introduction {#sec005}
============

*Plasmodium vivax*, which is the most widely distributed plasmodium species that infects humans \[[@pntd.0006987.ref001]\], is considered the key challenge to malaria elimination efforts outside Africa. This is largely due to the ability of *P*. *vivax* to relapse from dormant stages in the liver \[[@pntd.0006987.ref002]\]. These liver hypnozoites are undetectable with current diagnostic tools and treatment, which is currently limited to 8-aminoquinolines and cannot be safely prescribed to G6PD-deficient individuals \[[@pntd.0006987.ref003]\]. Thus, additional tools to target *P*. *vivax* are urgently needed \[[@pntd.0006987.ref004]\]. Vaccines could play an important role in the elimination of this parasite. However, as primary infections are likely to cause most of the clinical episodes and to contribute proportionately more to onward transmission than a single infection \[[@pntd.0006987.ref005]\], it will be essential to incorporate blood-stage antigens in a candidate vaccine to reduce blood stage parasitemia and gametocytemia in breakthrough infections.

*P*. *vivax* preferentially invades young red blood cells called reticulocytes. Invasion into these cells relies on the interaction between parasite proteins and reticulocyte receptors. A well-characterized ligand-receptor pair involved in invasion is the interaction of *P*. *vivax* Duffy binding protein (PvDBP) with the Duffy Antigen Receptor for Chemokines (DARC) \[[@pntd.0006987.ref006]\]. The virtual absence of *P*. *vivax* malaria in West Africa, where populations are generally DARC negative, highlights the central role of this pathway in *P*. *vivax* infection \[[@pntd.0006987.ref007]\]. PvDBP is a 140 kDa type 1 integral membrane protein that consists of seven regions: a leader peptide sequence and N-terminal region (region I), conserved cysteine-rich regions (regions II and VI), central uncharacterized regions (regions III to V), and a transmembrane region followed by a cytoplasmic domain. Region II (PvDBPII) contains three-subdomain (SD) protein, with SD2 contributing key residues for binding to DARC on red blood cells (RBCs) \[[@pntd.0006987.ref008], [@pntd.0006987.ref009]\]. It has been proposed that binding of PvDBPII with its receptor may lead to dimerization of PvDBPII \[[@pntd.0006987.ref010]\]. No functional role has yet been identified for central regions III to V of PvDBP. However, as they are conserved among isolates from various geographical regions \[[@pntd.0006987.ref011]\], the potential of antibodies against these regions as correlates of protective immunity against vivax malaria deserves investigation.

In highly endemic areas of PNG, naturally acquired immunity against *P*. *vivax* controls parasite densities leading to reduced risk of clinical disease in the second and third year of life \[[@pntd.0006987.ref012]\]. Immune responses to PvDBPII increase with age, suggesting they may play an important role in acquired immunity \[[@pntd.0006987.ref013]\]. Strong naturally acquired humoral immunity to PvDBPII has been associated with reduced risk of high-density parasitemia in PNG children \[[@pntd.0006987.ref014]\]. In addition, anti-PvDBPII antibodies purified from plasma from PNG individuals with the ability of blocking *P*. *vivax* invasion of reticulocytes provide the rationale of PvDBP as promising vaccine candidate \[[@pntd.0006987.ref015]\]. However, one of concerns related to the development of PvDBP as a vaccine candidate is that sequence diversity of PvDBPII may allow the evasion of human immune responses \[[@pntd.0006987.ref016], [@pntd.0006987.ref017]\]. In regions of PNG with high *P*. *vivax* endemicity, the most predominant allele of PvDBPII is AH with a proportion of 26% in circulating strains \[[@pntd.0006987.ref014]\]. In parallel to PvDBPII polymorphisms, antibody responses to PvDBPII showed strain-specific immunity to the *P*. *vivax* strains circulating in PNG \[[@pntd.0006987.ref014]\]. When antisera were tested for the presence of functional antibodies that block PvDBPII-DARC interaction, it was found that a small proportion of individuals (\<10%) were able to make high levels of binding inhibitory antibodies (BIAbs) that blocked binding of diverse strains \[[@pntd.0006987.ref018]\]. The presence of such high levels of BIAbs was associated with protection against *P*. *vivax* infection and reduced parasite densities \[[@pntd.0006987.ref018], [@pntd.0006987.ref019]\]. Although PvDBPII has significant polymorphisms, the binding residues for DARC are highly conserved, which makes the development of strain-transcending BIAbs possible \[[@pntd.0006987.ref018]\]. The reason why the development of such BIAbs is not common remains to be understood. Here, we used a functional binding inhibition assay to investigate the presence and association of anti-PvDBPII BIAbs and protection against clinical *P*. *vivax* malaria in young children in PNG of 1--3 years age.

Whole genome sequencing of Cambodian field isolates identified a second putative erythrocyte binding protein (PvEBP) with all the features of a *Plasmodium* erythrocyte-binding protein, including a N-terminal signal peptide, a Duffy-binding like domain (Region II, PvEBPII), a C-terminal cysteine-rich domain, and a transmembrane domain \[[@pntd.0006987.ref020]\]. Although harboring all the characteristics typical of DBP superfamily member, PvEBPII seems to be distant from PvDBP in phylogeny, and no inhibition of PvEBPII-reticulocyte binding was observed by using mouse anti-PvDBPII IgG \[[@pntd.0006987.ref021]\]. The genetic distance of PvEBPII and PvDBPII indicates that PvEBPII is not a recent gene duplication, and its apparently lower proportion of single nucleotide polymorphisms suggests that it is unlikely to be under the same level of immune selection as PvDBP \[[@pntd.0006987.ref021]\]. In a recent screen of 38 *P*. *vivax* antigens in plasma from naturally exposed children in PNG, antibodies to both PvDBPII and PvEBPII were frequently identified among five-antigen combinations with the strongest protective effects against clinical malaria \[[@pntd.0006987.ref022]\]. A more in-depth evaluation of the functional importance of antibody responses to variants of PvDBPII, PvDBPIII-V and PvEBPII is thus warranted.

The IgG isotype determines antibody function, and in humans, cytophilic IgG1 and IgG3 are important mediators of pathogen clearance. Numerous studies have reported that IgG subclass profiles differ among antibodies targeting different *P*. *falciparum* antigens \[[@pntd.0006987.ref023]--[@pntd.0006987.ref027]\]. The properties of the antigen appear to be one of the main determinants of the type of IgG subclass generated \[[@pntd.0006987.ref025]\]. In addition, for some *Plasmodium* antigens, a switch from a predominant IgG1 response in young children to an increase or even predominance of IgG3 response in older individuals is a characteristic feature of natural acquisition of clinical immunity to malaria \[[@pntd.0006987.ref028]--[@pntd.0006987.ref030]\]. It remains to be confirmed if this switch is due to a history of increased exposure and/or the maturing of the immune system. Elucidating the subclasses of IgG against different PvDBPII variants and PvEBPII, and their association with clinical diseases may help better understand the importance of development of IgG subclass immunity for protection against malaria.

*Plasmodium* infection is considered to be one of the key driving forces of the evolution of the human genome. Polymorphisms in RBC proteins are particularly common in malaria endemic regions \[[@pntd.0006987.ref031]--[@pntd.0006987.ref033]\]. Gerbich deficiency is associated with the deletion of exon 3 in the glycophorin C gene (*GYPCΔex3*) \[[@pntd.0006987.ref034]\]. Gerbich-negative erythrocytes were first identified in 1960 but are of low prevalence globally \[[@pntd.0006987.ref035]\]. However, in some Melanesian populations from PNG, 50% of them have inherited the Gerbich phenotype \[[@pntd.0006987.ref036]\]. Few studies have shown consistent associations between the Gerbich phenotype and *Plasmodium* infection \[[@pntd.0006987.ref037]--[@pntd.0006987.ref039]\], with one study observing a lower prevalence of *P*. *falciparum* infection among the population with this phenotype \[[@pntd.0006987.ref037]\]. Its potential association with protection against *P*. *vivax* and its relationship with the acquisition of immunity remains unknown.

In this study, parameters of naturally acquired immunity to four variants of PvDBP (several alleles of PvDBPII and PvDBPIII-V), as well as PvEBPII were characterized in PNG children of 1--3 years of age from a 16-month longitudinal cohort study. In addition, levels of total IgG to PvDBPII, IgG subclass, and presence of anti-PvDBPII BIAbs were measured and their association with *P*. *vivax* infection, clinical episodes, and Gerbich negativity was explored.

Material and methods {#sec006}
====================

Cohort study {#sec007}
------------

Plasma samples used in the current study were collected as part of a longitudinal cohort study of young PNG children (1 to 3 years old) previously described \[[@pntd.0006987.ref012]\]. In brief, participants were followed for up to 16 months, with visits twice/month for symptomatic illness and infection status as detected by microscopy and PCR. All *P*. *vivax* infections were genotyped, allowing for the calculation of the incidence of genetically distinct blood-stage infections acquired during follow-up (i.e. the molecular force of blood-stage infections, molFOB) \[[@pntd.0006987.ref040]\]. Host genotyping for the presence of the *GYPCΔex3* deletion associated with the Gerbich blood group was done by PCR, as previously described \[[@pntd.0006987.ref041]\]. Children who were homozygous for the *GYPCΔex3* deletion were considered to be Gerbich negative. Plasma samples collected at the start and at the end of the study from 224 children were used in the present study.

Purification of PvDBPII and PvEBPII recombinant proteins {#sec008}
--------------------------------------------------------

The four PvDBP variants used in this study were binding domain II from strains AH, O, P and Sal1 \[[@pntd.0006987.ref014]\]. The recombinant PvDBPII variants were expressed in *E*. *coli*. Proteins were solubilized from inclusion bodies, purified by affinity chromatography, followed by refolding and ion exchange chromatography as per methods described earlier \[[@pntd.0006987.ref042]\]. An 1176 bp fragment corresponding to the PvDBPIII-V region (aa 508--899) from Sal1 reference sequence was codon optimized for expression in *E*. *coli*. The protein was purified by metal affinity chromatography. Recombinant PvEBPII (aa 161--641) with a C-terminal 6-His tag was expressed as a soluble protein in *E*. *coli* SHuffle cells. Following cell lysis, the recombinant PvEBPII was purified from cell lysate as a soluble protein by metal affinity chromatography using standard procedures.

Measurement of IgG responses by Luminex bead assay {#sec009}
--------------------------------------------------

Recombinant PvDBPII, PvDBPIII-V, and PvEBPII fragments were conjugated to Luminex Microplex microspheres as previously described \[[@pntd.0006987.ref043]\]. To conjugate proteins to 2.5x10^6^ beads, we used 0.300 μg/mL of PvDBPII AH, 0.125 μg/mL of PvDBPII O, 0.094 μg/ mL of PvDBPII P, 0.225 μg/mL of PvDBPII Sal, 0.031 μg/mL of PvDBPIII-V and 0.250 μg/mL of PvEBPII. The Luminex multiplex bead-based antibody detection assay was performed as described elsewhere with the following modifications \[[@pntd.0006987.ref029], [@pntd.0006987.ref043]\]. Plasma samples were diluted 1:100 in PBS with 1% BSA and 0.05% Tween (PBT). Diluted samples were incubated with a mix of antigen-conjugated beads (0.1 uL of each bead position) (1:2) for 30 minutes under constant agitation. PE-conjugated donkey anti-human IgG Fc (0.1 mg/mL, Jackson ImmunoResearch) was used as a secondary antibody. IgG subclasses were detected using the following antibodies: mouse anti-human IgG1 hinge-PE (0.1 mg/mL, clone 4E3, Southern Biotech); mouse anti-human IgG2 Fc-PE (0.1mg/mL, clone HP6002, Southern Biotech); mouse anti-human IgG3 hinge-PE (0.1 mg/mL clone HP6050, Southern Biotech); or mouse anti-human IgG4 Fc-PE (0.1 mg/mL, clone HP6025, Southern Biotech). All these antibodies were diluted 1:100 in PBS to detect total IgG, IgG1, IgG2, IgG3, and IgG4 respectively. Beads were read on a Bio-Plex 200 reader set for 75 beads per analyte. Results were reported as median fluorescence intensity (MFI). One blank well without plasma was used for determination of the true fluorescence background. Positive controls consisted of pooled serum from immune PNG adults (\>18 years) from the Madang (n = 10) and East Sepic Provinces (n = 10) who were highly exposed to malaria. Such positive controls were included in ten two-fold serial dilutions (1:50--1:25600) as pervious described \[[@pntd.0006987.ref029]\]. Negative control sera in all assays were from the same individual, which was from the Australia Red Cross donor. The donor was anonymous resident of Melbourne, Australia with no known previous exposure to malaria.

PvDBPII--DARC binding assays {#sec010}
----------------------------

An ELISA plate-based semi-quantitative binding assay was used to test binding of PvDBPII with DARC and estimate the binding inhibitory activity of serum as described earlier \[[@pntd.0006987.ref044]\]. Briefly, the N-terminal 60 amino acid extracellular region of DARC was expressed as a fusion with Fc region of human IgG (nDARC-Fc), purified using protein A column and used to coat ELISA plates. Recombinant PvDBPII was incubated with nDARC-Fc coated plates in the presence of different concentrations of anti-PvDBPII serum or purified anti-PvDBPII IgG. Bound PvDBPII was detected with anti-PvDBPII rabbit sera followed by anti-rabbit IgG horse radish peroxidase (HRP)-conjugated goat antibodies. Percent binding inhibition was determined at different serum or IgG concentrations using a standard curve as previously described \[[@pntd.0006987.ref044]\].

Statistical analyses {#sec011}
--------------------

Standard curves from each Luminex assay plate were used for transformation of MFIs into relative antibody units (expressed as dilution factors that range from 1.95 x 10^−5^ or 1/51200 to 0.02 or 1/50) using a five parametric logistic regression model as described previously \[[@pntd.0006987.ref029]\]. Statistical analyses were performed using STATA version 12 (StataCorp) and R version 3.2.1 (htpp://cran.r-project.org). Spearman\'s rank correlation was used to assess the associations between antibody levels and age, and correlations among antibody responses against different antigens. Differences in antibody reactivity between categorical variables were assessed using Wilcoxon signed-rank sum test (for two groups) and Kruskal Wallis test (for multiple groups). Differences in proportions were evaluated by chi-square test. Antibody responses were used to predict molecular force of blood stage infection (molFOB) using a general linear model (GLM) stratified by concurrent infection status at the last visit of the study. Concurrent infection was defined as positive if PCR test was positive at the time of antibody measurement (i.e. enrollment). Antibody levels were stratified into tertiles to analyze the relationship with prospective risk of clinical *P*. *vivax* episodes (defined as axillary temperature \> 37.5°C or history of fever in the preceding 48 hours with a concurrent parasitemia \> 500 *P*. *vivax* /μl) and prevalence of infection diagnosed by PCR and light microscopy over the 16 months of follow-up \[[@pntd.0006987.ref012]\]. Generalized estimating equation (GEE) with exchangeable correlation structure and semi-robust variance sandwich estimator were used and analyses were done by comparing the incidence rate ratio (IRR) of clinical malaria between the highest and lowest tertiles, and medium and low antibody levels groups. Differences in geometric mean parasitemia and incidence of clinical episodes among *GYPCΔex3* genotypes were analyzed using GEE.

To examine the effect of combining antibody responses to different antigens on the risk of clinical disease, we examined all possible combinations of 2 and 3 antigens. For this, IgG responses for each antigen were assigned a score starting from 0 to 3 for low, medium or high antibody levels (i.e. quartiles). These scores were then added up for each different combination. The scores of any combination were equally divided into three groups and used in our GEE model.

All datasets were available in the Dryad repository: <https://doi.org/10.5061/dryad.n14p52b> \[[@pntd.0006987.ref045]\].

Ethics statement {#sec012}
----------------

Ethics clearance was obtained from the PNG Medical Research and Advisory Committee (MRAC 05.19) and the Walter and Eliza Hall Institute (HREC 07/07) for the use of field samples. All parents/guardians of the participants signed a consent form prior to enrollment. The Melbourne control sample was obtained under ethics approval HREC 13/07.

Results {#sec013}
=======

Total IgG levels against PvDBPII and PvEBPII in children {#sec014}
--------------------------------------------------------

The pooled serum from immune PNG adults was assumed to represent the equilibrium antibody levels to all antigens achieved following repeated natural exposure. Here, we determined at enrollment the number of children who had already acquired IgG levels equivalent to \>50%, \>25%, \>10%, \>5%, or \>1% of the IgG levels in adults ([Table 1](#pntd.0006987.t001){ref-type="table"}). Plasma from the PNG children were reactive to all four PvDBPII alleles and PvEBPII. However, total IgG levels were relatively low for the most common PvDBPII PNG variant AH, with only 25.9% and 3.6% of children achieving \>5% and \>25% of hyper-immune adult levels respectively. Immunogenicity of other PvDBPII alleles and PvEBPII were similar (range: 14.3--20.1%, \>5% of hyper-immune adult levels) ([Table 1](#pntd.0006987.t001){ref-type="table"}).

10.1371/journal.pntd.0006987.t001

###### Total and IgG subclasses responses to PvDBP and PvEBP in Papua New Guinean children.

![](pntd.0006987.t001){#pntd.0006987.t001g}

  Protein        Antibody   Geom mean[\*](#t001fn002){ref-type="table-fn"}   95% CI          No. of children (%)                                        
  -------------- ---------- ------------------------------------------------ -------- ------ --------------------- ------------ ----------- ----------- ----------
  PvDBPII AH     IgG        0.26                                             0.22     0.32   164 (73.2)            58 (25.9)    21 (9.4)    8 (3.6)     4 (1.8)
                 IgG1       0.64                                             0.54     0.75   220 (98.2)            123 (54.9)   59 (26.3)   21 (9.4)    7 (3.1)
                 IgG3       0.33                                             0.26     0.43   118 (52.7)            79 (35.3)    35 (15.6)   7 (3.1)     2 (0.9)
  PvDBPII O      IgG        0.44                                             0.37     0.53   131 (58.5)            32 (14.3)    14 (6.3)    4 (1.8)     2 (0.9)
                 IgG1       1.23                                             1.07     1.41   185 (82.6)            62 (27.7)    29 (12.9)   8 (3.6)     3 (1.3)
  PvDBPII P      IgG        0.38                                             0.31     0.45   130 (58.0)            45 (20.1)    17 (7.6)    7 (3.1)     3 (1.3)
                 IgG1       0.99                                             0.84     1.17   180 (80.4)            88 (39.3)    35 (15.6)   10 (4.5)    5 (2.2)
  PvDBPII Sal1   IgG        0.28                                             0.23     0.33   164 (73.2)            43 (19.2)    17 (7.6)    6 (2.7)     3 (1.3)
                 IgG1       0.55                                             0.48     0.64   205 (91.5)            120 (53.6)   45 (20.1)   17 (7.6)    7 (3.1)
  PvDBPIII-V     IgG        0.29                                             0.24     0.35   137 (61.2)            38 (17.0)    17 (7.6)    5 (2.2)     2 (0.9)
                 IgG1       1.66                                             1.45     1.89   219 (97.8)            168 (75.0)   80 (35.7)   25 (11.2)   13 (5.8)
  PvEBP          IgG        0.12                                             0.09     0.16   86 (38.4)             37 (16.5)    27 (12.1)   13 (5.8)    9 (4.0)
                 IgG1       0.45                                             0.36     0.58   135 (60.3)            80 (35.7)    53 (23.7)   25 (11.2)   14 (6.3)

Abbreviation: No = number; Geom mean = geometric mean; 95% CI = 95% confidence interval.

\*Values multiplied by 1000. Values in arbitrary units were interpolated from standard curves by using a 5PL logistic regression model.

Total IgG levels were strongly correlated between all proteins measured at the beginning of the cohort study (rho = 0.67--0.98, P\<0.001), with the strongest correlation found between PvDBPII AH and PvDBPII O variants. Total IgG to PvEBPII shows weak to moderate correlation with different PvDBP antigens (Spearman's rho = 0.22--0.63) ([Fig 1](#pntd.0006987.g001){ref-type="fig"}). Similar correlation patterns were observed in the plasma samples collected at the last time point of the longitudinal study (rho = 0.22--0.99, P≤0.001) ([S1 Fig](#pntd.0006987.s002){ref-type="supplementary-material"}).

![Heat map representation of the correlation between total and IgG subclass responses to PvDBPII variants and PvEBPII at enrolment.\
The heat map colors correspond to the Spearman correlation coefficient and range from 0 (no correlation, blue) to 1 (strong correlation, yellow). P\<0.001--0.899.](pntd.0006987.g001){#pntd.0006987.g001}

Immune responses in relation to infection, age, and cumulative exposure {#sec015}
-----------------------------------------------------------------------

The prevalence of *P*. *vivax* infection was 55.4% (124/224) among young PNG children at enrolment, as determined by PCR ([Fig 2A](#pntd.0006987.g002){ref-type="fig"}). Individuals with a concurrent *P*. *vivax* infection by PCR had significantly higher IgG levels (P\<0.015) to all variants of PvDBPII, PvDBPIII-V and PvEBPII ([Fig 2A](#pntd.0006987.g002){ref-type="fig"} and [S1 Table](#pntd.0006987.s006){ref-type="supplementary-material"}), indicating that even asymptomatic *P*. *vivax* infections may boost immune responses to PvDBP and PvEBPII in settings of high *P*. *vivax* endemicity.

![**Distribution of antibody responses by the presence of malaria infection (A) and age (B).** The X-axis represented log10 transformed antibody responses and the Y-axis represented the observed distribution of the antibody responses. Individuals without infection were shown in red and with infection in blue. Infection was determined by PCR at enrollment **(A).** Children were categorized into \< 21 months of age (n = 112) and ≥ 21 months of age (n = 112) **(B)**. P values were calculated using Wilcoxon-signed rank test. P\<0.05 was considered significant.](pntd.0006987.g002){#pntd.0006987.g002}

We examined the relationship between total IgG antibody levels with age and cumulative exposure, which was defined as the product of age and the corresponding individual molFOB \[[@pntd.0006987.ref040]\]. Collectively, both categorical and continuous measures of antibody levels were positively correlated with age and cumulative exposure for PvDBPII AH and PvEBPII (P\<0.001--0.047), and PvDBPIII-V with a borderline significance (P = 0.051), but only in children free of *P*. *vivax* infection at enrolment ([Fig 2B](#pntd.0006987.g002){ref-type="fig"} and [S1 Table](#pntd.0006987.s006){ref-type="supplementary-material"}). This might reflect that the acquisition of clinical immunity in this cohort of young children was mainly driven by individual exposure heterogeneity \[[@pntd.0006987.ref040]\]. To further understand the associations of antibody responses with prevalence of infection in the longitudinal cohort study, antibody responses to PvDBPII AH and PvEBPII were found associated with increased risk of infection detected by PCR for the study period ([S2 Table](#pntd.0006987.s007){ref-type="supplementary-material"}).

In addition, higher antibody levels were observed in the last visit for PvDBPII AH, PvDBPIII-V, and PvEBPII compared to their levels at enrolment ([S2 Fig](#pntd.0006987.s003){ref-type="supplementary-material"}). IgG antibodies to PvDBPIII-V and PvEBPII were indeed significantly correlated with molFOB at the last visit (rho = 0.15, P≤0.020), with a borderline significance for PvDBPII AH (rho = 0.12, P = 0.070) ([S2 Fig](#pntd.0006987.s003){ref-type="supplementary-material"}).

IgG subclasses to PvDBP and PvEBPII {#sec016}
-----------------------------------

In PNG adults, IgG1 was the predominant antibody subclass for all PvDBPII proteins ([S3 Fig](#pntd.0006987.s004){ref-type="supplementary-material"}). IgG2 and IgG3 were the subdominant antibody subclasses, with substantially higher amounts of IgG3 detected against the most common PvDBPII AH variant than the other strains. Balanced responses with detectable amounts of IgG1 and IgG3 antibodies were found for PvDBPIII-V and PvEBPII. No detectable levels of IgG4 were observed for any of the antigens tested ([S3 Fig](#pntd.0006987.s004){ref-type="supplementary-material"}).

Between 27.7--75.0% of the children had levels of IgG1 against PvDBPII and PvEBPII that were \>5% of the IgG1 levels observed in adults to all antigens tested. However, only a small subset of children (range: 3.6--11.2%) had IgG1 levels exceeding 25% of adult levels ([Table 1](#pntd.0006987.t001){ref-type="table"}). In contrast to what was observed in adults, children showed a strong IgG1 predominance among antibodies to PvEBPII. Detectable levels of IgG3 were observed for PvDBPII AH and PvEBPII, both in much lower levels than IgG1, suggesting that acquisition of IgG1 was faster than IgG3 for both PvEBPII and PvDBP antigens. Polarization from IgG1 towards IgG3 was only identified for PvDBPII AH, as suggested by the decreasing ratio of IgG1/IgG3 with increase in age (rho = -0.24, P\<0.001). No detectable levels of IgG2 and IgG4 were observed for any of the antigens tested among these children.

PCR-positive children had increased IgG1 for PvDBPII AH, PvDBPII O, and PvEBPII ([S1 Table](#pntd.0006987.s006){ref-type="supplementary-material"}). Consistent with the patterns observed for total IgG, significant increase in IgG1 with age and cumulative exposure were identified for PvDBPII AH and PvEBPII in PCR negative children (rho = 0.25--0.42, P≤0.013) but not in those with concurrent infections ([S1 Table](#pntd.0006987.s006){ref-type="supplementary-material"}). Increases in IgG3 against PvDBPII AH and PvEBPII were significantly associated with age and cumulative exposure (rho = 0.19--0.39, P≤0.044) ([S1 Table](#pntd.0006987.s006){ref-type="supplementary-material"}).

Total IgG to PvDBP and PvEBPII reduces the risk of clinical malaria {#sec017}
-------------------------------------------------------------------

Children with medium and high levels of IgG to PvDBPII AH allele had 31% and 44% reduction in the risk of a *P*. *vivax* clinical episodes, respectively, compared to children with low antibody levels (adjusted incidence risk ratio medium versus low antibody levels (aIRR~M~ 0.69, 95% CI: 0.49--0.98, P = 0.037); high versus low antibody levels (aIRR~H~ 0.56, 95% CI, 0.40--0.77, P \<0.001) ([Fig 3](#pntd.0006987.g003){ref-type="fig"} and [S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}). IgG to PvDBPII O showed similar, but slightly lower significant protective association ([Fig 3](#pntd.0006987.g003){ref-type="fig"} and [S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}). Therefore, total IgG responses to PvDBPII AH and PvDBPII O may be biomarkers of protective immunity. Only children with high IgG antibody levels to PvDBPII P, PvDBPII Sal1 and PvDBPIII-V had a significant reduction in the risk of *P*. *vivax* malaria. Antibodies to PvEBPII correlated with stronger protection than all variants of PvDBPII (aIRR~M~ = 0.73, P = 0.022; aIRR~H~ = 0.26, P\<0.001, [Fig 3](#pntd.0006987.g003){ref-type="fig"} and [S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}) and in a multivariate model, only antibodies to PvEBPII remained independently associated with protection against clinical malaria ([S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}).

![Association between total and IgG subclasses to four PvDBPII variants, PvEBPII and protection against clinical malaria (density\>500 parasite/ul) in 224 young Papua New Guinean children.\
Data were plotted as exposure (molFOB), age, season and village of residency adjusted incidence rate ratios and 95% confidence intervals. Incidence rate ratios, 95% confidence intervals and P-values from GEE models. P\<0.05 were deemed significant. ^**\***^ denotes P\<0.05, \*\* denotes P\<0.01, \*\*\* denotes P\<0.001.](pntd.0006987.g003){#pntd.0006987.g003}

We further examined the possible effect of combining antibody levels against PvDBPs and PvEBPII on the risk of clinical disease. Combinations of PvDBPII AH and PvEBPII showed evidence of an increased protective effect (aIRR = 0.30, 95% CI, 0.19--0.46, P\<0.001, [S4 Table](#pntd.0006987.s009){ref-type="supplementary-material"}**)**. Combinations of 3 antigens did not show an additional increase in protection ([S4 Table](#pntd.0006987.s009){ref-type="supplementary-material"}).

IgG subclass responses to PvDBP and PvEBPII and risk of clinical disease {#sec018}
------------------------------------------------------------------------

For all of the antigens tested, with the exception of PvDBPII O, high levels of IgG1 were associated with decreased risk of clinical malaria in the adjusted models (aIRR~H~ = 0.38--0.70, P ≤ 0.027) ([Fig 3](#pntd.0006987.g003){ref-type="fig"} and [S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}). For IgG3 responses, the analysis was restricted to PvDBPII AH and PvEBPII as detectable antibody levels were only observed for them. Both PvDBPII AH and PvEBPII responses also showed a protective effect (aIRR~H~ = 0.55--0.68, P≤0.021). In a multivariate model incorporating IgG1 and IgG3 for all antigens, only IgG3 to PvDBPII AH and IgG1 to PvEBPII remained associated with clinical protection (aIRR = 0.38--0.63, P ≤ 0.006) ([S3 Table](#pntd.0006987.s008){ref-type="supplementary-material"}).

Anti-PvDBPII binding inhibitory antibodies against diverse *P*. *vivax* strains {#sec019}
-------------------------------------------------------------------------------

Plasma obtained at first (n = 8) and last visit (n = 8) exhibited substantial binding inhibitory antibodies against diverse PvDBPII alleles ([Table 2](#pntd.0006987.t002){ref-type="table"}). Binding inhibitory antibodies against the three PvDBPII variants was also significantly correlated (P\<0.001) with the highest correlation observed between the two most prevalent alleles PvDBPII AH and PvDBPII O (rho = 0.66, P\<0.001).

10.1371/journal.pntd.0006987.t002

###### Blocking activity of antibodies against different PvDBPII alleles.

![](pntd.0006987.t002){#pntd.0006987.t002g}

                Enrolment (n = 168)                                     End of follow-up (n = 162)                                                      
  ------------- --------------------- ---------------- ---------------- ---------------------------- ---------------- ---------------- ---------------- -------
  Median OD     37                    36.4             34.9                                          41.3             42.3             38.6             
  IQR           \[23.4, 50.2\]        \[25.0, 45.5\]   \[24.0, 47.2\]                                \[28.6, 52.6\]   \[32.0, 49.8\]   \[29.4, 45.9\]   
  Min--max      0--100                0--100           0--99.4                                       0--100           0--100           0--100           
  **≥80%**                                                                                                                                              
  n positive    6                     6                8                6                            7                6                7                6
  \% positive   3.57%                 3.57%            4.76%            3.57%                        4.32%            3.70%            4.32%            3.70%
  **60--79%**                                                                                                                                           
  n positive    12                    9                10               8                            11               10               10               8
  \% positive   7.14%                 5.36%            5.95%            4.76%                        6.79%            6.17%            6.17%            4.94%

Abbreviations: IQR = interquartile range.

Twelve children (7.14% of 168 tested) had ≥60% blocking activity for at least one variant of PvDBPII. Eight children (4.76%) had high levels (≥80% blocking activity) of inhibition to one variant, six of which showed high blocking activity against all three variants. Children with concurrent *P*. *vivax* infections showed moderate-high blocking activity (\>60% blocking against all three alleles, PCR positive: 13.3% vs. PCR negative: 3.5%, P = 0.027). Although median blocking activity did not vary with age (P\>0.19), five of the six children with high levels of inhibitory, strain-transcending antibodies were older than 21 months of age (P = 0.115).

Blocking activity in plasma samples collected at the end of follow-up was very similar to the start of the study ([Table 2](#pntd.0006987.t002){ref-type="table"}). After 16 months of additional exposure, concurrent *P*. *vivax* infections were no longer associated with an increase in blocking activity. Only three children (1.9%) had high blocking antibodies (≥80%) against all three variants at both time points. Among the three children with constant high blocking activity, two (66.7%) were homozygous for the Gerbich blood group (i.e. *GYPC*Δ*ex3*) compared to 14 (10.5%) in those with lower or no blocking activity (P = 0.036).

When assessing the association between the ability of antibodies to block PvDBPII binding to red blood cells and prospective risk of *P*. *vivax* malaria, children with high blocking ability against AH (IRR = 0.44, P = 0.059), O (IRR = 0.52, P = 0.119), Sal1 (IRR = 0.52, P = 0.081), or all three alleles combined (IRR = 0.45, P = 0.083) at enrolment showed a tendency for a reduced incidence of *P*. *vivax* episodes of any density ([Table 3](#pntd.0006987.t003){ref-type="table"}). These effects were almost entirely due to the three children with high strain-transcending blocking activity at both enrolment and end of follow-up (IRR = 0.16, 95% CI, 0.03--1.04, P = 0.055).

10.1371/journal.pntd.0006987.t003

###### Association of anti-PvDBPII binding inhibitory antibodies and protection against subsequent *P*. *vivax* malaria.
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  Antigens   Levels of inhibition   Pv any density   Pv \> 500/μl                                      
  ---------- ---------------------- ---------------- -------------- ----- ------- ------ ------ ------ -------
  AH         60--79%                1.08             0.7            1.8   0.761   0.81   0.43   1.54   0.518
             ≥80%                   0.44             0.2            1.0   0.059   0.53   0.19   1.54   0.245
  O          60--79%                1.02             0.6            1.8   0.951   0.93   0.47   1.85   0.844
             ≥80%                   0.52             0.2            1.2   0.119   0.71   0.28   1.8    0.47
  Sal 1      60--79%                1.07             0.6            1.8   0.789   1.17   0.62   2.2    0.636
             ≥80%                   0.54             0.3            1.1   0.081   0.56   0.23   1.36   0.201
  All 3      60--79%                1.04             0.6            1.9   0.901   1.58   0.63   3.92   0.326
             ≥80%                   0.45             0.2            1.1   0.083   0.42   0.1    1.75   0.234

Abbreviation: IRR = incidence rate ratio; 95% CI = 95% confidence interval. IRR is for responders of high level and medium level versus those of low levels, 95% confidence intervals and P values are obtained from GEE models. P values \<0.05 were deemed significant.

Neither blocking nor total IgG antibodies to any of the *P*. *vivax* proteins showed any protective association with the risk of *P*. *falciparum* clinical episodes, but all children with high levels of total IgG were associated with increased episodes of clinical *P*. *falciparum* malaria, suggesting antibodies against PvDBP and PvEBP were correlates of increased risk of *P*. *falciparum* exposure ([S5 Table](#pntd.0006987.s010){ref-type="supplementary-material"}).

Gerbich-negativity is associated with higher antibody responses, lower *P*. *vivax* parasitemia, and lower risk of clinical disease {#sec020}
-----------------------------------------------------------------------------------------------------------------------------------

In this study, 29 children harbored Gerbich phenotype caused by double deletion of exon 3 of *GYPC* gene, 111 of them with single deletion of the same region named as heterozygote and other 84 were without any deletion called wild-type. Children with Gerbich phenotype had a reduced risk of malaria episodes in comparison to those with wild-type, and the strength of this relationship increased with increasing parasite densities (aIRR = 0.69, 95%CI = 0.41--1.01, P = 0.040, for *P*. *vivax* \>500 parasites /μL; aIRR = 0.53, 95%CI = 0.28--1.00, P = 0.050 for \>2,000 parasites /μL; aIRR = 0.40, 95%CI = 0.17--0.94, P = 0.036 for \>10,000 parasites /μL; [Table 4](#pntd.0006987.t004){ref-type="table"}). Similarly, the geometric mean parasitemia was significantly lower in children with homozygous Gerbich phenotype than those with wild-type (P = 0.003).

10.1371/journal.pntd.0006987.t004

###### Association between Gerbich negativity and incidence of clinical malaria during follow-up in 1--3 year PNG children.
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  Clinical malaria    Wild Type (n = 84)   Heterozygote (wt/Δ3, n = 111)   Gerbich negativity (Δ3/Δ3, n = 29)                                                              
  ------------------- -------------------- ------------------------------- ------------------------------------ ----- ----- ------ ----- ------ ------ ------ ------------ -----------
  All episodes        395                  102.2                           3.86                                 479   135   3.55   122   35.5   3.44   0.82   0.65--1.03   0.088
  All *Pf* episode    228                  102.2                           2.23                                 259   135   1.92   75    35.5   2.11   0.81   0.60--1.08   0.154
  *Pf*\>2500/ul       169                  102.2                           1.65                                 195   135   1.44   56    35.5   1.58   0.84   0.58--1.21   0.343
  All *Pv* episodes   220                  102.2                           2.15                                 257   135   1.90   54    35.5   1.52   0.69   0.48--0.98   **0.040**
  *Pv*\>500/ul        134                  102.2                           1.31                                 168   135   1.24   34    35.5   0.96   0.64   0.41--1.01   0.054
  *Pv*\>2000/ul       93                   102.2                           0.91                                 114   135   0.84   21    35.5   0.59   0.53   0.28--1.00   **0.050**
  *Pv*\>10000/ul      40                   102.2                           0.39                                 44    135   0.33   6     35.5   0.17   0.40   0.17--0.94   **0.036**

Abbreviation: PYAR = person year at risk; aIRR = adjusted incidence rate ratio; Pf = *Plasmodium falciparum*; Pv = *Plasmodium vivax*.

**\***aIRR were shown the comparison between homozygotes and wild-type group by applying GEE models with analysis adjusted for the following potential confounders: the village of residence, age, the season of recruitment, and force of infection. P\<0.05 were deemed significant.

Children with wild-type phenotype had the lowest levels of antibodies against all PvDBP variants, while homozygotes had the highest levels to almost all antigens (P\<0.011--0.046), except for PvEBPII (P = 0.501) ([Fig 4](#pntd.0006987.g004){ref-type="fig"}). These results suggested that *GYPCΔex3* may contribute to the acquisition of antibodies to PvDBP but not to PvEBPII in PNG children.

![Gerbich blood type correlates with stronger antibody responses for PvDBPII variants.\
The overall differences among three groups by red blood cell phenotype were compared using Kruskal-Wallis one-way analysis, and individual comparison of each two groups was tested by Wilcoxon signed-rank sum method, star represents the comparison to wild-type group. P\<0.05 were deemed significant. ^**\***^ denotes P\<0.05, \*\* denotes P\<0.01, \*\*\* denotes P\<0.001.](pntd.0006987.g004){#pntd.0006987.g004}

Discussion {#sec021}
==========

This study confirmed that total IgG and infrequently detected BIAbs against PvDBPII were associated with an overall lower incidence rate of clinical vivax malaria in young children who were developing clinical immunity to *P*. *vivax*. Antibody responses against PvDBPII were higher in those Gerbich-negative, a common red blood cell polymorphism within the East Sepik region of PNG. We also observed a strong association with protection for total IgG and IgG1 antibodies to PvEBPII, but no difference by Gerbich phenotype.

In this study, only 4.8% (8/168) of the young children aged 1 to 3 years had acquired high levels of BIAbs (\> 80% binding inhibition) against at least one PvDBPII allele, with six children exhibiting binding-inhibitory antibodies against diverse strains, while none of them had obtained levels higher than of 90% of BIAbs against any PvDBPII allele. An earlier study among school-age children (5--9 years) in PNG identified 9% of children with BIAbs \>90% to PvDBPII \[[@pntd.0006987.ref018]\] and in the Brazilian Amazon, 26.6% and 20.5% of the residents of all age groups presented \>80% and \>90% BIAbs activity to PvDBPII \[[@pntd.0006987.ref019]\]. In these two studies \[[@pntd.0006987.ref018], [@pntd.0006987.ref019]\], high anti-PvDBPII BIAbs activity blocked diverse strains. The overall lower detection of high-levels PvDBPII BIAbs in our study indicate that acquisition of BIAbs is at least partially related to the increase in life-time malaria exposure. However, the observation that BIAbs are not common even in adult population with high levels of *P*. *vivax* exposure indicates that these functional blocking antibodies are difficult to acquire under conditions of natural exposure. Nevertheless, since the target epitope of BIAbs to PvDBPII was conserved \[[@pntd.0006987.ref046]\], once PvDBPII BIAbs are acquired, they may provide strain transcending binding inhibitory activity, even in young children with limited and developing clinical immunity.

In contrast to the DARC conserved binding residues, polymorphisms thought to be associated with immune evasion \[[@pntd.0006987.ref010]\] are common throughout nonfunctional regions of PvDBPII distal to the binding site of DARC. Our study and previous reports show that these regions of PvDBPII are exposed to the immune system resulting in observable immune responses to PvDBPII generated at a young age, even in our cohort of young children with limited immunity \[[@pntd.0006987.ref014], [@pntd.0006987.ref018]\]. However, antibody responses to these polymorphic PvDBPII regions are likely to be strain-specific \[[@pntd.0006987.ref014]\] and potentially not functionally associated with clinical protection \[[@pntd.0006987.ref018], [@pntd.0006987.ref019]\]. In this young cohort of PNG children, IgG to the dominant variants PvDBPII AH and O were both more prevalent and strongly associated with protection against clinical vivax-malaria in the adjusted models. As such, total IgG responses to these PvDBPII variants may serve as biomarkers for protective immunity.

Regions II and VI of PvDBP are cysteine-rich domains and under immune selection, while regions III to V do not have a known function \[[@pntd.0006987.ref008]\]. Nevertheless, one study in *P*. *falciparum* showed that antibodies to regions III-V of PfEBA175 and PfEBA140 could inhibit *P*. *falciparum* invasion \[[@pntd.0006987.ref047]\]. Our study showed that antibodies to region III-V predicted protection from vivax clinical malaria. However, antibody titers to region III-V were significantly correlated to antibodies against some PvDBPII variants and did not retain a significant association with protection in the multivariate models. Future functional studies will be required to investigate the potential functional role of antibodies to region III-V of PvDBP.

Among all antigens tested, the strongest association of protection from vivax malaria was identified for PvEBPII. In one previous study, PvEBPII was characterized as a functionally and antigenically distinct *P*. *vivax* ligand with a stronger binding preference for Duffy-positive than Duffy-negative reticulocytes *in vitro* \[[@pntd.0006987.ref021]\], suggesting that although antigenically distinct from PvDBP, it may function as a redundant invasion pathway when immune activity blocks the principal PvDBPII-DARC pathway. The relatively low correlation between antibody responses to PvDBP and PvEBPII indicates co-acquisition of antibodies to both antigens, rather than cross-reactivity between them. Combination of PvDBPII AH and PvEBPII immune responses offered a further increase in protection against clinical vivax-malaria and thus supports the inclusion of these two antigenically distinct ligands in a combination vaccine. PvEBPII should be further investigated as a potential vaccine candidate, and the efficacy of anti-PvEBP antibodies will need to be confirmed in functional assays.

Some polarization of IgG1 towards IgG3 was only identified for PvDBPII AH, as similar switch towards a balanced IgG1/IgG3 response was observed in the narrow age range of our study population. The possible reason for this might be related to the higher circulation of AH strain in this setting, thus young children might be exposed to the AH strain enabling them to acquire higher IgG3 to AH. Apart from the possible higher exposure, by comparing with other alleles included in this manuscript, AH was shown to have two special mutations K371E and K386Q, both of which were mapped to SD2. As most of the PvDBPII polymorphism are in this subdomain, our results suggest that these two mutations were important for immune reactivity to PvDBPII AH. Whereas, after a longer period of immune exposure to other strains, including O, P and Sal1, significantly higher levels of IgG3 to them were also observed in the adults. Consistent with previous reports \[[@pntd.0006987.ref025], [@pntd.0006987.ref028]\], these results indicated that IgG3 switching may be driven by the nature of the antigen and influenced by exposure and maturation of the immune system. In multivariate models of isotype-specific responses, for IgG3 against PvDBPII AH and high IgG1 to PvEBPII were significantly associated with a reduced risk of clinical vivax-malaria. It remains to be confirmed whether IgG1 and IgG3 antibodies target different epitopes and/or differ in their functionality or if they simply differ in their utility as correlates of risk of future infection or protection against vivax malaria.

In addition to antibody-mediated protection against vivax malaria, it is believed that specific red blood cell polymorphisms can induce resistance to clinical malaria \[[@pntd.0006987.ref033]\]. There is limited evidence that individuals with Gerbich negativity may have a lower risk of *P*. *falciparum* and/or *P*. *vivax* infection \[[@pntd.0006987.ref037]\]. Our longitudinal study now provides the first indication for a protective role of the Gerbich phenotype with reduction of *P*. *vivax* malaria among young children aged 1 to 3 years with limited clinical immunity. However, Gerbich negativity was not associated with significant protection against blood-stage infection in school-aged children (5--14 years) from another PNG longitudinal cohort study \[[@pntd.0006987.ref039]\]. It is assumed that the acquired, clinical immunity among older semi-immune children and immune adults may mask the protective effects of specific genotypes against uncomplicated malaria infection \[[@pntd.0006987.ref039]\]. In this study, a higher proportion of Gerbich homozygotes was found among children with high titers of PvDBPII-specific BIAbs. This was consistent with a previous observation that children with the South-East Asian ovalocytosis (SAO, caused the *SLC4A1Δ27* deletion in the human Band 3) were 3.3 times more likely than non-SAO children to have high levels of PvDBPII-specific BIAbs \[[@pntd.0006987.ref048]\]. The mechanism by which Gerbich affects anti-PvDBP antibody responses is unknown and will require further investigation.

In summary, our study highlights the association of total antibody and BIAbs to PvDBPII variants with lower risk of clinical *P*. *vivax* malaria episodes in PNG children and further strengthens the rationale for PvDBPII as a potential vaccine antigen. Interestingly, both naturally acquired immunity to PvDBPII and Gerbich homozygosity showed significant protection against *P*. *vivax*. Antibodies to PvEBPII were more strongly association with clinical protection against *P*. *vivax* malaria in these young children. Further studies will be needed to clarify the mechanism of protection afforded by Gerbich and the importance of PvEBPII in *P*. *vivax* reticulocyte invasion and immune protection.
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###### STROBE statement---Checklist of items that should be included in reports of cohort studies.

(DOC)

###### 

Click here for additional data file.

###### Heat map representation of the correlation of antibody responses to PvDBP variants and PvEBPII at enrollment and end of the cohort study.

The heat map colors correspond to the Spearman's correlation coefficient, ranging from 0 (no correlation, blue) to 1 (strong correlation, yellow). P\<0.001--0.152.

(TIF)

###### 

Click here for additional data file.

###### The relationship of antibody responses to PvDBP variants and PvEBPII and individual exposure.

**(A)** The comparison of antibody levels between enrolment and end of the cohort study. Red represents the first visit and blue represents the last visit. P values were calculated using Wilcoxon signed-rank sum method. P values \<0.05 were considered significant. **(B)** Association of antibody levels from the last visit of the study and the molecular force of blood stage infection (molFOB). The blue lines show the association between antibody responses and molFOB predicted by linear regression models. The shaded regions depict the variation in the data (95% prediction interval). X-axis: molFOB, y-axis: total IgG antibody responses for each antigen. P values are from general linear model. P values and were deemed significant if \<0.05.

(TIF)
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Click here for additional data file.

###### IgG subclasses response patterns among PNG adults and young children.

Antibody levels of crude mean fluorescence intensity (MFI) were log10 transformed. Solid lines represent antibody levels among adults in a two-fold serial dilution starting from 1/50. Only the median antibody levels among children for each subclass (IgG1, IgG2 and IgG3) were presented by dashed lines.

(TIF)

###### 

Click here for additional data file.

###### The distribution of crude antibody responses of total IgG, IgG1, IgG2 and IgG3 to PvDBP and PvEBPII at enrollment.

Antibody levels of crude mean fluorescence intensity (MFI) were shown in X axis and count of each level were represented in Y axis. Antibody levels of total IgG, IgG1, IgG2 and IgG3 were depicted in pink, yellow, blue, and light slate blue respectively.

(TIF)
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###### Associations between IgG and IgG subclasses to PvDBP and PvEBPII with measures of concurrent and cumulative exposure.

(XLSX)
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###### Association between antibodies and prevalence of *P. vivax* infection diagnosed by PCR.

(XLSX)

###### 

Click here for additional data file.

###### Association between antibodies and risk of clinical *P. vivax* malaria.

(XLSX)
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###### The association of combination of antibody responses and risk of *P. vivax* malaria.

(XLSX)
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Click here for additional data file.

###### Association between antibodies and risk of clinical *P. falciparum* malaria.

(XLSX)

###### 

Click here for additional data file.
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